Investigation of vancomycin use at 108 Military Central Hospital
Main Article Content
Keywords
Abstract
Objective: To describe ovancomycin use at 108 Military Central Hospital. Subject and method: A retrospective study was conducted on 61 medical records with vancomycin use at 108 Military Central Hospital from January 2020 to June 2020. Result: Mean age of patients was 59.9 years, the proportion of male patients was 75.4%. Discharge outcome: 68.9% with complete or partial recovery; 29.5% with death or worse outcome. Vancomycin was mainly prescribed empirically (90% with empirical indications and 10% with definitive indications). Microbiology tests were indicated in 96.7% of patients, of which 72.1% patients had positive results. Staphylococcus aureus was the most common gram (+) pathogen, of which 59.1% was MRSA. Loading dose was not used in 90% of patients. The most common maintenance dosing regimen was 1g every 12 hours (59.7%). However, this regimen was used on patients with very wide range of renal function (Clcr varied from 15.8ml/min to 155.3ml/min). Nephrotoxicity was occurred in 15 of 61 patients (24.6%), 13 patients of whom used concomitant medications with nephrotoxicity. Conclusion: The majority of patients weren’t received the loading dose (90%). The common maintenance dosing regimen was 1g every 12 hours, which was indicated in patients with various renal function (Clcr varied from 15.8ml/min to 155.3ml/min). The result of the study was very important basis for the implementation of a protocol for therapeutic monitoring of vancomycin.
Article Details
References
2. Bệnh viện Bạch Mai (2019) Quy trình giám sát nồng độ thuốc trong máu và hiệu chỉnh liều vancomycin ở bệnh nhân người lớn của Bệnh viện Bạch Mai.
3. Álvarez Rocío, López Cortés Luis E et al (2016) Optimizing the clinical use of vancomycin. Antimicrobial agents and chemotherapy 60(5): 2601-2609.
4. American Society of Health-System Pharmacists (2009) Therapeutic monitoring of vancomycin in adults patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 66: 82-98.
5. Baptista JP, Sousa E et al (2012) Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents, 39(5): 420-423.
6. Drew HR, Sakoulas G (2018) Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults. Dostopno na: https://www. uptodate. com/contents/vancomycin-parenteral-dosingmonitoring-and-adverse-effects-in-adults.
7. Martin JH, Norris R et al (2010) Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev 31(1): 21-24.
8. NB Provincial Health Authorities Anti-Infective Stewardship Committee (2018) Vancomycin dosing and monitoring guidelines.
9. Rybak MJ, Le J et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 77(11): 835-864.
10. Schulz TL, Pietruszka HM et al (2018) Intravenous vancomycin use - adult - inpatient/ambulatory clinical practice guideline.